
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA is positioned favorably due to its innovative approach in targeting neurodegenerative diseases through advanced therapeutics that leverage proprietary technologies and focus on protein misfolding. The promising results from its PD active immunotherapy ACI-7104.056, which has shown a significant 20-fold increase in antibodies against pathogenic variants of aSyn, highlight the potential for impactful clinical advancements and successful upcoming trial readouts. Moreover, the ongoing NLRP3 program, particularly in conjunction with the positive expectations surrounding the EVOKE trial for Alzheimer's disease patients, suggests an increasing interest in the company's offerings, further solidifying a positive outlook for its future prospects.
Bears say
AC Immune SA concluded the quarter with a significant net operating loss of CHF 16.2 million, indicating financial stress. The company operates in a high-risk environment characterized by potential unfavorable clinical outcomes, regulatory uncertainties, and increasing complexity in pricing and market dynamics for its therapeutic candidates. These fundamental financial challenges, alongside the inherent risks associated with the biopharmaceutical industry, contribute to a negative outlook for AC Immune's stock.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares